Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shogun Maitake
London, Ontario, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Shogun Maitake's lead extract, Odaira Black Maitake Extract (OBME), shows pre-clinical evidence of anti-cancer activity (inducing cancer cell death and immune response) and is in academic research collaboration for further development, including potential combinations with immunotherapies. There is no evidence of company-sponsored IND or clinical development; product is marketed as a dietary supplement[2][5].
- Therapeutic areas
- OncologyMetabolic DisordersImmunology
- Modalities
- BiologicNatural extract
- Industry
- Food & Nutrition
02
Partnerships
University of WindsorMedical institutions and universities internationally (exact names not listed)[2][5]
Beyond the preview
Go deeper on Shogun Maitake.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shogun Maitake.